Sun Pharmaceutical Industries Limited FII & DII Activity
5-Day Flow Trend
| Date | FII Net (₹ Cr) | DII Net (₹ Cr) |
|---|---|---|
| 2026-10-28 | +871.83 | +643.35 |
| 2026-10-27 | −1462.49 | +2609.57 |
| 2026-10-26 | −1462.49 | +2609.57 |
| 2026-10-23 | +887.65 | +3235.36 |
| 2026-10-22 | −3458.70 | +2891.32 |
Today's Institutional Flow
Foreign Institutional Investors (FII) record a net cash inflow of ₹ 871.83 Cr into Indian equities, while Domestic Institutional Investors (DII) add ₹ 643.35 Cr on the same day. Together the two groups bring roughly ₹ 1.52 trillion of fresh money into the market, reinforcing a broadly bullish tone. In the equity‑specific view, Sun Pharmaceutical Industries Limited (SUNPHARMA) sees no block or bulk trades reported today, indicating that the substantial cash inflows are being distributed across other securities rather than concentrated in large‑size transactions in this stock.
Trend vs 5‑Day Average
The day's FII cash surge contrasts sharply with the five‑day average FII outflow of ₹ ‑894.74 Cr, signalling a reversal from a period of net selling to a pronounced buying episode. Conversely, DII activity remains comfortably above its five‑day mean of ₹ 2,592.03 Cr, showing that domestic funds continue to sustain a steady pace of accumulation.
F&O Positioning Data
FII participation in futures and options (F&O) climbs to a net exposure of ₹ 643,395 Cr, underscoring a heavy tilt toward derivatives contracts. Their index‑future positioning reveals a long/short ratio of 1.2, indicating a modest preference for bullish exposure relative to bearish bets.
Healthcare Sector Flow
The healthcare sector, anchored by firms like SUNPHARMA, has witnessed a consistent inflow from both FII and DII over the past week, reflecting growing investor confidence in the segment's growth prospects.
Market-wide FII/DII data — same for all F&O stocks. Date: 2026-10-28